Abstract
Molecular analyses

The basic aspects of molecular and cell biology are not only integral part of biomedical research but are increasingly becoming also relevant for patient care. The genetic material of all living organisms is made up of DNA that in its entirety makes up the individual's genome. Genomics aim at the unravelling of the complete genetic information of an individual's genome
. In the context of the human genome organization project the complete sequence of the human genome was established almost 10 years ago [2, 3] . [9, 10] . In this context it was recently shown that only patients with wild-type KRAS or wild-type BRAF tumours benefit from cetuximab or panitumumab [11] [12] [13] [14] [15] . Therefore, by determining the KRAS status before therapy allows predicting whether the patient will benefit from cetuximab ( Fig. 1 [19, 20] . [14] . [21] [22] [23] [24] . In another study it was shown that a specific polymorphism resulting in a inosine triphosphatase deficiency protects from ribavirin induced haemolysis that presents a frequent problem in patients with chronic hepatitis C undergoing antiviral treatment [25] . [26] [27] [28] [29] . Through these genome-wide association [3] [30, 31] , restless legs syndrome [32] , sporadic amyotrophic lateral sclerosis [33] or multiple sclerosis [34] . Further [38, 39] .
In order to utilize the sequence information from the human genome organization project for research as well as for clinical applications and to define the function(s) of newly identified genes, strategies were developed to globally analyse genomic DNA sequences as well as their cell-, tissue-or organ-specific expression profile that are collectively termed 'functional genomics'.
An important instrument of functional genomics are array analyses which are based on the complementary base-pairing of single-stranded DNA or RNA (genes) to form a double-stranded hybrid (hybridization). This principle has been successfully utilized for several decades for the analysis and characterization of DNA (Southern Blot) und RNA (Northern Blot
)
Mutations and diseases
Polymorphisms
A single nucleotide polymorphism (SNP) is a mutation/ base substitution in a defined locus of the human genome that occurs in the population at a frequency of Ͼ1%. A practical example of significant epidemiological and clinical interest is the interleukin (IL)-28B gene that codes for interferon . For this gene 3 variants/ genotypes have been identified (haplotypes for alleles 1 and 2): T/T, C/C and T/C. The frequency of these genotypes in the general population depends among others from the individual's ethnic background: T/T is most frequent in Africans (60-80%) while in Asians genotype C/C predominates (about 90%).
Polymorphisms and diseases or disease predispositions
Staying with the example of the polymorphisms of the IL-28B gene it was found that it has a major impact in patients with a hepatitis C virus (HCV) infection. Patients with the IL-28B genotype C/C eliminate the HCV infection spontaneously or during antiviral therapy much more frequently than patients with genotype T/T. Patients with genotype T/C have an intermediary frequency of spontaneous elimination or response to therapy
HapMap project
In the context of the international HapMap consortium there is a genome-wide search for polymorphisms of four ethnically different populations and their association with human diseases
Signature analyses -omics
With the determination of the complete sequence of the human genome [2, 3] [40] . [41] . 
folding) structural genomics aim at the definition of the complete folding inventory of a newly identified protein in order to define its potential functions. These methodologies increasingly allow an insight into cellular pathways and biological networks that are collectively termed 'systems biology' [1]. This approach should allow to further optimize the diagnosis, therapy and prevention of human diseases and to contribute to the prediction of the individual's prognosis and response to therapy
The array technologies allow to simultaneously analyse tens of thousands of genes and their expression at the mRNA and/or protein level. It is thus possible to identify an individual gene or gene expression signature in malignant tumours or tumour-associated cells or tissues (microenvironment) that permits to predict the individual patient's prognosis and/or the response to a specific drug. In addition, pharmacogenetic analyses based on the individual's genomic DNA (pharmacogenetics) increasingly allow to predict the efficacy as well as potential side effects of drugs (individualized pharmacotherapy)
In the following text, the contribution of signature analyses to the understanding of the pathogenesis, the prediction of the natural course and the clinical management of patients will be illustrated for selected clinical examples.
Lymphoma
One of the very first clinical applications of the DNA chip technology was in patients with a diffuse large cell B cell lymphoma (DLBCL). The gene expression signatures allowed to defining two molecular subgroups with different prognosis and clinical risk
Breast cancer
Based on a signature of RAS and other dysregulated genes in tumour tissues, a new classification of breast cancer was recently
proposed [45] . Further, DNA microarray analyses of 70 genes defined two different gene expression profiles [46] . These allow predicting the prognosis of the disease ('good prognosis signature' versus 'poor-prognosis signature'), also with respect to the risk of lymph node metastases and tumour recurrence [47] , as well as the response to chemotherapy [48] . In another study it could be shown that the amplification of HER2 in the breast cancer predicts the therapeutic efficacy of anthracyclines [49] . Further, Liu et al. [50] [51] . Array signatures thus reflect a major advance of medicine from a more empirical clinical management to an individually 'tailored' medicine based on the individual patient's genetic profile [52] .
Lung cancer
Based on proteome analyses it became possible to more precisely categorize the histology of lung tumours and to clearly distinguish between primary lung tumours and lung metastases [53] . Additional studies recently revealed that the individual prognosis of patients with non-small cell lung cancer (NSCLC) can be predicted by a 5-gene signature [54, 55] . Further, in a recent case report metabolomics could predict the response to treatment with the TKI erlotinib in a patient with a subtype of NSCLC [56] .
Prostate cancer
Metabolomic profiles were able to distinguish between benign prostate, localized prostate cancer and metastatic disease and identified sarcosine as an important metabolic intermediary involved in prostate cancer cell invasion and aggressiveness [57] . Further, metabolomics allowed predicting the risk of recurrence [58] .
Hepatocellular carcinoma
The HCC is world-wide frequent malignancy with an epidemiologically and genetically very heterogeneous background [59] [60] [61] . The gene and gene expression profiles of HCCs and their relevance for the patients' prognosis were analysed in numerous studies [62] [63] [64] . Depending on the etiological background of the underlying chronic liver disease a 3-gene and a 120-gene signature, respectively, were identified that allow distinguishing between dysplasia and neoplasia [61] . In addition, transcriptome analyses of HCCs identified several genes which suggest a novel HCC classification with therapeutic implications [65] . Further, microarray analyses of 6000 genes in completely resected HCCs showed that 12 genes predict a high risk for an early intrahepatic recurrence [66] [67] . Other miR species have recently been identified that are involved in HCC development (miR221; [68] ), HCC invasion and metastasis (miR-30d; [69] ) as well as the prognosis of patients with this malignancy (miR-29; [70] ). 
Cholangiocellular carcinoma
Non-malignant diseases
Recently it was discovered that specific miR species affect the biology of HCV, i.e. miR199a effectively suppresses HCV replication and thus may represent a novel antiviral strategy for patients with chronic HCV infection [72, 73] . Further, in patients with chronic hepatitis C a specific gene signature in liver tissue seems to predict the progression of chronic hepatitis C to liver fibrosis and cirrhosis [74, 75] . Metabolomics was also shown to have an impact on the diagnosis of celiac disease using serum or urine [76] . 
Conclusions and perspectives
